Yonina Murciano-Goroff

Our paper in @Nature demonstrates diverse alterations leading to resistance to G12C inhibition. We must continue to work to advance treatments on behalf of our patients with KRAS mutant cancers nature.com/articles/s4158…

At #ESMO25, join @YoninaMG to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. @MSKCancerCenter @myESMO Learn more: bit.ly/4nafnUa

Dr. Yonina Murciano-Goroff (@YoninaMG) studies early drug development for #cancer. At #AACR23, she shared new research into how she's using biomarkers and genomic data from MSK-IMPACT® to identify effective treatments for patients.

Selpercatinib in the neoadjuvant setting for RET fusion + NSCLC: frontiersin.org/articles/10.33…

@JTOonline @alexdrilon A great collaboration aimed at preventing RET fusion + CNS mets in NSCLC. bit.ly/3pYNkio @alexdrilon @AlexiaIasonos

Nearly 1/2 of patients w/RET fusion+ stage IV #NSCLC develop brain metastases. Not only is #selpercatinib associated w/decreased rates of progression of #CNS disease, but early initiation may prevent development of #CNS metastases. bit.ly/3pYNkio @alexdrilon @YoninaMG

@SewantiLimaye @ullas_batra @RAJATRAJ @MSKCancerCenter @RonaYaeger @RFhospital A rockstar international team addressing a critically important topic for patients! - @CDebyaniPhD Dr. Greg Riely @RonaYaeger @DrMrinalGounder @SewantiLimaye @ullas_batra @RAJATRAJ @bhuvanchugh Dr. Vijay Agarwal

Great discussions on #KRAS in lung and pancreas with excellent moderations by @ullas_batra @RAJATRAJ for @MSKCancerCenter MTB ! Great talks by Dr Greg Riely and @YoninaMG @RonaYaeger Waiting to witness the section on colorectal case, kras resistance @RFhospital @DrMrinalGounder

@oncmom17 @MSKCancerCenter I learn so much from @oncmom17 and am ever grateful to be her colleague as well!

@MSKCancerCenter @YoninaMG So proud to call Dr Murciano-Goroff my colleague!

@CDebyaniPhD @OncoKB @cbioportal I had the best company for dinner, and it's inspiring to see all of the transformative work coming out of this group! @CDebyaniPhD @OncoKB @cbioportal

And the @OncoKB & @cbioportal teams got to have dinner with this superstar on our last night #AACR2023 !

Today at #AACR23, @YoninaMG will present results of a first-in-human phase 1 study of LY3537982 — a highly selective #KRAS G12C inhibitor in people with advanced solid tumors with this mutation — at 2:35 in the Chaplin Theater. bit.ly/43y41Rn

Drs. @YoninaMG @alexdrilon and team report on CNS disease in #RET fusion-positive NSCLC with selpercatinib @JTOonline. In pts with CNS metastases, only 20% with CNS progression at 3y. In pts without brain metastases, 0% (!) had CNS metastases at 3y. #LCSM jto.org/article/S1556-…

RT: Featured today by @MSKLibrary: Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies dx.doi.org/10.1038/s41467…

The fourth most visited short article published in @natrevclinoncol in 2022 is: nature.com/articles/s4157…

Fantastic collaboration with @YoninaMG, @alexdrilon, @MFBerger1, @StadlerZsofia and @MskccCMO. We analyze our #MSKIMPACT clinical sequencing cohort for evidence of germline BRCA1/2 mediated tumorigenesis in non-BRCA-associated cancers. 1/5

Our work on BRCA1/2 reversion mutations in a pan-cancer cohort reveals a BRCA-mediated phenotype in non-canonical histologies. Kudos to a great team! @alexdrilon @chaiband @AliSchram @YJanjigianMD @StadlerZsofia @MFBerger1 nature.com/articles/s4146…

Great work on KRAS G12C! aacrjournals.org/cancerdiscover…

Huge thanks and Kudos to all the authors and collaborators @RonaYaeger @Rosenlab1 @LoweLabMSKCC @r_mezzadra @DSolit @MFBerger1 @YoninaMG @Mirati @BoundlessBio 💪💪💪and @CD_AACR and Michele Hartsough for the amazing work together! Ad Maiora!

Excited to share work done with many collaborators @MSKCancerCenter and showing that ctDNA testing expands access to life-prolonging therapy for patients with lung cancer! @MSK_RadOnc nature.com/articles/s4159…

Hello, 3rd ed! The print version is out in a few weeks. The digital version is available now on Kindle and other e-readers. Congratulations to @NouraChoudhury @YoninaMG @NeilVasan and the many contributing authors!! amazon.com/gp/aw/d/B0B9T5…

#Genetics has become an integral part of #cancercare. Dr. Zsofia K. Stadler & Kelsey Breen invite you to the Hereditary Cancer Genetics course @MSKCancerCenter featuring expert faculty in #hereditarycancer syndromes: vimeo.com/730372325 Register at: bit.ly/HereditaryCanc…

New! Although positive germline findings are prevalent in diverse, pan-cancer patients, Black patients are less likely to get recommended genetics care compared to White patients—and this disparity could affect cancer outcomes and families. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… CC: @OncoAlert

Important to have clinical trial options for patients with PTHS / germline PTEN mutant tumors futuremedicine.com/doi/10.2217/fo…